We revealed that there was no significant difference in the rate of HCC development between patients in whom AFP decreased to <5.3 ng/mL and those in whom AFP remained <5.3 ng/mL at the EOT (Fig 6). This evidence concerns the gene AFP and hepatocellular carcinoma.